Last reviewed · How we verify
HK-660S
At a glance
| Generic name | HK-660S |
|---|---|
| Sponsor | CuromeBiosciences |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis (PHASE2)
- Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HK-660S CI brief — competitive landscape report
- HK-660S updates RSS · CI watch RSS
- CuromeBiosciences portfolio CI